2 results
Approved WMOCompleted
To assess the analgesic efficacy, safety, and tolerability of once daily orally administered GRT6005 in a total of 3 fixed doses (i.e., 200 µg, 400 µg, and 600 µg GRT6005) compared to placebo in subjects with moderate to severe chronic LBP.
Approved WMOCompleted
Primary purpose: study the feasibility of a new treatment option based on biofeedback in people with intellectual disabilities.Secondary purpose: explore effects of treatment for swallowing problems in people with intellectual disabilities.